This legal maneuver follows ONT’s growing global effort to enforce its intellectual property rights in several jurisdictions, including the United States, the United Kingdom, and now Australia. The heart of the dispute centers around whether MGI’s sequencing systems make unauthorized use of ONT’s nanopore technology, which uses biological pores to read DNA sequences in real time—a platform ONT has heavily invested in and patented over the past decade.
ONT has previously accused BGI and its subsidiaries of developing rival products that allegedly mirror core features of ONT’s systems, including sample preparation and signal processing methods. In Australia, ONT believes MGI is planning—or already attempting—to commercialize sequencing platforms that may violate these patents.
Justice Ian Jackman’s ruling permits ONT to scrutinize documents to determine whether a full patent infringement lawsuit is warranted. However, the court also struck down ONT’s notice to produce boardroom communications and privileged legal advice, calling that part of the request a “fishing expedition” without enough foundation.
Despite that setback, the court acknowledged that ONT had “reasonable cause” to believe that it may have a right to relief—essentially confirming the legitimacy of ONT’s concerns. The judge noted that ONT had already gathered “material” suggesting overlapping technical features between MGI’s products and ONT’s protected technologies.
The court’s decision reflects the delicate balance in IP law between protecting innovators and preventing frivolous lawsuits. Preliminary discovery ensures that businesses like ONT can investigate credible concerns without launching immediate full-blown litigation, which can be both costly and reputationally damaging.
This latest legal development reinforces how fiercely competitive the global genomics industry has become, especially as technologies like nanopore sequencing become increasingly commercialized for clinical and research use. A successful suit in Australia could have far-reaching implications, including potential product bans, licensing deals, or multimillion-dollar damages.
